Johnson & Johnson – Strategic Developments and Clinical Milestones

Johnson & Johnson (NYSE: JNJ) is a global healthcare company operating across consumer health, pharmaceuticals, and medical devices. On 14 September 2026, two major developments surfaced that are likely to influence the company’s strategic trajectory and market perception.

1. Potential divestiture of the DePuy Synthes orthopedic division

Several reports indicate that J&J is in advanced negotiations to sell its DePuy Synthes orthopedic business to Apollo Global Management, a private‑equity firm.

  • Source details: Bloomberg News, ProInvestor, Pulse2, and Private Equity Wire all cited anonymous sources confirming the discussions. The sale, if completed, would be valued at approximately $20 billion.
  • Market reaction: The announcement prompted a rise in J&J shares, as reflected in a 0.29 % increase in the Dow Jones index on the day of the news.
  • Strategic context: The DePuy Synthes unit has historically contributed a significant portion of J&J’s medical‑device revenue. A divestiture would free capital and streamline the company’s focus on high‑growth therapeutic segments.

2. Clinical advancement of RYBREVANT® (amivantamab‑vmjw)

J&J’s bispecific antibody therapy, RYBREVANT®, has shown a clinically meaningful benefit in patients with EGFR exon 20 insertion‑positive non‑small cell lung cancer.

  • Key data: A Phase‑3 study reported a median overall survival of 34 months, the longest observed in this patient population to date.
  • Regulatory status: The results were released via a press release on PR Newswire.
  • Implications: This success strengthens J&J’s position in the bispecifics market, which analysts project will grow substantially over the next decade. The company’s focus on bispecific antibody development aligns with broader industry trends toward multi‑specific therapeutics.

3. Market environment and company fundamentals

  • Stock performance: As of 10 September 2026, J&J’s share price closed at $265.58, below the 52‑week high of $281.07 and above the 52‑week low of $173.33.
  • Financial metrics: The company’s market cap is approximately $640 billion, with a price‑to‑earnings ratio of 30.79.
  • Business scope: J&J manufactures a wide array of products—including skin and hair care, acetaminophen, pharmaceuticals, diagnostic equipment, and surgical devices—sold worldwide.

4. Industry outlook

The bispecifics market is expected to experience substantial growth between 2026 and 2036, driven by an expanding pipeline and increasing therapeutic adoption. J&J’s RYBREVANT® positions it well to capture a share of this momentum.

These developments illustrate J&J’s dual strategy of divesting non‑core assets while advancing high‑impact therapeutics. The outcomes of the DePuy Synthes transaction and the long‑term performance of RYBREVANT® will likely be key determinants of the company’s financial health and market valuation in the coming years.